首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1532466

反義和RNAi治療市場- 技術（RNA干擾、反義RNA）、給藥途徑（鞘內、靜脈內、皮下）、應用（神經退化、癌症、皮膚、遺傳性疾病） - 全球預測（2024年至2032年）

Antisense and RNAi Therapeutics Market - Technology (RNA Interference, Antisense RNA), Route of Administration (Intrathecal, Intravenous, Subcutaneous), Application (Neurodegenerative, Cancer, Skin, Genetic Disorders) - Global Forecast (2024 - 2032)

出版日期: 2024年05月16日 | 出版商:

Global Market Insights Inc. | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在研究和開發的不斷發展以及臨床試驗的擴大的推動下，全球反義和 RNAi 治療市場將於 2024 年至 2032 年以 18.2% 的複合年成長率成長。持續的研發努力導致創新療法的發現和遞送機制的改進，從而增強反義和 RNAi 治療的功效。此外，臨床試驗的擴大驗證了這些進步並支持它們通過監管途徑的進展。正在進行的研究和強力的試驗活動的協同作用促進了市場成長，增加了這些先進治療解決方案的可用性和採用。

例如，2023年8月，Sirnaomics Ltd.成功完成了其STP707 RNAi治療研究的第一階段，在治療對先前治療無反應的晚期癌症患者的多種實體瘤方面顯示出積極的結果。這項進展凸顯了 RNAi 療法在解決其他療法失敗的複雜腫瘤病例方面的潛力，增強了基於 RNAi 的解決方案的吸引力。它可能會推動對 RNAi 療法的投資和研究增加，擴大市場機會，並驗證 RNAi 技術在癌症治療中的有效性。

反義和 RNAi 治療行業根據技術、給藥途徑、應用和地區進行分類。

受其實用性和患者友善性的推動，皮下注射細分市場到 2032 年將經歷顯著的改善。皮下注射允許以相對簡單的技術和最小的不適來進行治療，使其成為長期治療的理想選擇。這種給藥途徑也非常適合需要頻繁給藥或自行給藥的治療，從而提高患者的依從性。隨著反義和 RNAi 療法的進步，皮下注射的便利性和效率使其成為臨床廣泛使用的首選方法。

由於腫瘤學標靶治療的需求不斷增加，2024 年至 2032 年間，癌症領域將大幅成長。反義和 RNAi 技術提供了精確的機制來沉默與癌症進展相關的基因，從而提供創新的治療方法。隨著對癌症基因組學理解的進步，這些療法對於制定個人化醫療策略變得至關重要。改善患者治療效果和克服癌症治療抗藥性的巨大潛力推動了該領域在市場上的主導地位。

由於該國醫療保健產業的快速成長和對生物技術的投資不斷增加，亞太地區反義和 RNAi 治療市場佔有率從 2024 年到 2032 年將出現顯著的複合年成長率。該地區不斷擴大的患者群體、慢性病盛行率的上升以及政府的支持性政策推動了對先進治療解決方案的需求。此外，大量的研發活動，加上醫療保健基礎設施的改善，進一步推動了市場成長。亞太地區的策略進步和投資使其成為反義和 RNAi 治療產業擴張的重要貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - 神經退化性疾病和遺傳性疾病的盛行率不斷增加
  - 基因表現和傳遞技術相關研究的投資不斷增加
  - RNAi 和反義療法的監管批准數量成長
  - 人們對基於 RNA 的療法的認知不斷提高
- 產業陷阱與挑戰
  - 臨床研究需要大量投資
  - 基於 RNA 的療法成本高昂
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
RNA干擾
反義RNA

第 6 章：市場估計與預測：按給藥途徑，2021 - 2032 年

主要趨勢
靜脈注射
鞘內注射
皮下注射
其他給藥途徑

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
心臟代謝和腎臟疾病
癌症
神經退化性疾病
遺傳性疾病
傳染病
眼科疾病
皮膚病
其他應用

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Arrowhead Pharmaceuticals, Inc.
Benitec Biopharma Inc.
BioNTech SE.
CRISPR Therapeutics
GlaxoSmithKline plc
Ionis Pharmaceuticals, Inc.
Novartis AG
OliX Pharmaceuticals, Inc.
Orna Therapeutics, Inc.
Percheron Therapeutics Ltd.
Sanofi
Sarepta Therapeutics, Inc.
Silence Therapeutics

簡介目錄

Product Code: 9517

Global Antisense and RNAi Therapeutics Market will grow at an 18.2% CAGR during 2024 and 2032, propelled by growing research and development coupled with the expansion of clinical trials. Continuous R&D efforts lead to the discovery of innovative therapies and improvements in delivery mechanisms, enhancing the efficacy of antisense and RNAi treatments. Moreover, the expansion of clinical trials validates these advancements and supports their progression through regulatory pathways. This synergy of ongoing research and robust trial activities fosters market growth, increasing the availability and adoption of these advanced therapeutic solutions.

For instance, in August 2023, Sirnaomics Ltd. successfully completed Phase I of its STP707 RNAi therapeutic study, showing positive results in treating multiple solid tumors in late-stage cancer patients unresponsive to previous treatments. This development highlights the potential of RNAi therapies to address complex oncology cases where other treatments have failed, enhancing the appeal of RNAi-based solutions. It may drive increased investment and research in RNAi therapeutics, expand market opportunities, and validate the effectiveness of RNAi technology in cancer treatment.

The antisense and RNAi therapeutics industry is divided based on technology, route of administration, application, and region.

The subcutaneous injections segment will experience a marked upturn through 2032, driven by its practicality and patient-friendly nature. Subcutaneous injections allow for the administration of therapeutics with relatively simple techniques and minimal discomfort, making them ideal for long-term treatments. This route of delivery is also well-suited for therapies requiring frequent dosing or self-administration, enhancing patient adherence. As antisense and RNAi therapeutics advance, the convenience and efficiency of subcutaneous injections position them as the preferred method for widespread clinical use.

The cancer segment will witness a considerable surge between 2024 and 2032, attributed to the increasing demand for targeted treatments in oncology. Antisense and RNAi technologies offer precise mechanisms for silencing genes associated with cancer progression, providing innovative treatment approaches. As the understanding of cancer genomics advances, these therapies are becoming crucial for developing personalized medicine strategies. The significant potential for improving patient outcomes and overcoming drug resistance in cancer treatment drives the dominance of this segment in the market.

Asia Pacific antisense and RNAi therapeutics market share will register a noteworthy CAGR from 2024 to 2032, owing to the country's rapidly growing healthcare sector and increasing investment in biotechnology. The region's expanding patient population, rising prevalence of chronic diseases, and supportive government policies drive the demand for advanced therapeutic solutions. Additionally, substantial research and development activities, coupled with improvements in healthcare infrastructure, further boost market growth. Asia Pacific's strategic advancements and investments make it a vital contributor to the expansion of the antisense and RNAi therapeutics industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of neurodegenerative and genetic disorders
  - 3.2.1.2 Growing investments in research related to gene expression and delivery technologies
  - 3.2.1.3 Growth in regulatory approvals for RNAi and antisense therapeutics
  - 3.2.1.4 Rising awareness towards RNA-based therapeutics
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Requirement for significant investments in clinical studies
  - 3.2.2.2 High cost of RNA-based therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 RNA interference
5.3 Antisense RNA

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Intravenous injections
6.3 Intrathecal injections
6.4 Subcutaneous injections
6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cardiometabolic & renal disorders
7.3 Cancer
7.4 Neurodegenerative disorders
7.5 Genetic disorders
7.6 Infectious diseases
7.7 Ophthalmic diseases
7.8 Skin diseases
7.9 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa